What is the administration frequency for benralizumab after initial doses?

Benralizumab is a monoclonal antibody used as an add-on maintenance therapy for individuals with severe asthma with eosinophilic phenotype. After the initial dosing schedule, which typically involves administering the medication more frequently during the first few doses, the recommended administration frequency shifts to once every 8 weeks. This dosing schedule is designed to sustain the therapeutic effects of the medication while minimizing the burden on the patient through less frequent administration.

This every-8-week regimen allows for effective maintenance of asthma control, leveraging the sustained biological activity of the drug. While other options suggest shorter intervals, the established practice is to optimize treatment by balancing efficacy and convenience, which is well represented by the every-8-week dosing following the initial loading doses.